Patents by Inventor Progenics Pharmaceuticals, Inc.

Progenics Pharmaceuticals, Inc. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRYSTAL FORMS OF (R)-N-METHYLNALTREXONE BROMIDE AND USES THEREOF
    Publication number: 20140004188
    Abstract: The present invention provides a new forms of (R)—N-methylnaltrexone, and compositions thereof, useful as a peripheral mu opioid receptor antagonist.
    Type: Application
    Filed: November 21, 2012
    Publication date: January 2, 2014
    Inventors: Progenics Pharmaceuticals, Inc., Wyeth, LLC
  • SYNTHESIS OF R-N-METHYLNALTREXONE
    Publication number: 20130323286
    Abstract: This invention relates to stereoselective synthesis of R-MNTX and intermediates thereof, pharmaceutical preparations comprising R-MNTX or intermediates thereof and methods for their use.
    Type: Application
    Filed: November 7, 2012
    Publication date: December 5, 2013
    Applicant: PROGENICS PHARMACEUTICALS, INC.
    Inventor: Progenics Pharmaceuticals, Inc.
  • METHODS FOR REDUCING VIRAL LOAD IN HIV-1 INFECTED PATIENTS
    Publication number: 20130216526
    Abstract: This invention provides a method of reducing viral load in an HIV-1-infected human subject which comprises administering to the subject an effective HIV-1 viral load reducing dose of a CCR5 receptor antagonist, such as a humanized antibody designated PRO 140 or an anti-CCR5 receptor monoclonal antibody, wherein the viral load reducing dose achieves an average maximum decrease of viral load in the subject of at least 1.83 log10 to 2.5 log10 at about ten days following administration of the CCR5 receptor antagonist and wherein the viral load reducing dose further achieves a mean viral load reduction of 1.7 log10 at about nine days following administration of the CCR5 receptor antagonist.
    Type: Application
    Filed: September 17, 2012
    Publication date: August 22, 2013
    Applicant: Progenics Pharmaceuticals, Inc.
    Inventor: Progenics Pharmaceuticals, Inc.